Yükleniyor... / Loading...
This study looks at the effect of the drug donepezil on cognitive dysfunction, and the genetic risk factors for that dysfunction, in people who have been treated for and recovered from a brain tumor. English-speaking patients aged 18 and older who had received cranial irradiation and/or chemotherapy and were in stable remission could take part. The study was carried out in Phase 1 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * diagnosed with a brain tumor and treated with cranial irradiation and/or chemotherapy, and in stable remission of their disease at the time of enrollment. * completed radiation and/or chemotherapy treatment at least 6 months prior to being enrolled in the study. * who obtain a Mini-Mental Status Examination (MMSE) score ranging from 18 to 28 at the time of enrollment. * are at least 18 years of age. * are English speaking. * have capacity to give consent Exclusion Criteria: * Patients with active or progressive disease on recent MRI of the brain either at the time of enrollment, or during the study period. * with a pre-existing uncontrolled seizure disorder, or significant renal or hepatic impairment. * taking the following medications: antipsychotics, psychostimulants. * patients who have been on selective serotonin re-uptake inhibitors (SSRIs) for less than 3 months at the time of enrollment. * with uncontrolled behavioral or mood disturbances. * have their anticonvulsant medication(s) or dosage(s) changed less than 30 days prior to enrollment. * currently receiving donepezil or other cholinesterase inhibitors. * who is pregnant. * unable to cooperate or complete cognitive tests.